{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(5)"],"submitter":["Lakkunarajah S"],"pubmed_abstract":["There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at least 6 weeks of adjuvant therapy were included. The primary objective was to assess the influence of dose index (DI) and relative dose intensity (RDI) on DFS and OS at 3 and 5 years in patients receiving fluorouracil-based doublet therapy with oxaliplatin (FOLFOX) (5-FU and oxaliplatin assessed separately), or capecitabine monotherapy. In the capecitabine group, DFS rates for 3 and 5 years were 66.7% and 57.6%, respectively, while OS rates were 80.3% and 66.7%, respectively. Those who received FOL"],"journal":["Current oncology (Toronto, Ont.)"],"pagination":["4031-4041"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8535138"],"repository":["biostudies-literature"],"pubmed_title":["The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis."],"pmcid":["PMC8535138"],"pubmed_authors":["Zhang H","Yamanaka E","Lakkunarajah S","Warner A","Breadner DA","Welch S"],"additional_accession":[]},"is_claimable":false,"name":"The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis.","description":"There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at least 6 weeks of adjuvant therapy were included. The primary objective was to assess the influence of dose index (DI) and relative dose intensity (RDI) on DFS and OS at 3 and 5 years in patients receiving fluorouracil-based doublet therapy with oxaliplatin (FOLFOX) (5-FU and oxaliplatin assessed separately), or capecitabine monotherapy. In the capecitabine group, DFS rates for 3 and 5 years were 66.7% and 57.6%, respectively, while OS rates were 80.3% and 66.7%, respectively. Those who received FOL","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-05-29T20:29:00.642Z","creation":"2025-05-29T20:29:00.642Z"},"accession":"S-EPMC8535138","cross_references":{"pubmed":["34677260"],"doi":["10.3390/curroncol28050342"]}}